Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan D Michelson

Showing results (111-120 of 124) with videos related to

Pageof 13
Sort By:
Blood|July 31, 2015
Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopeniaAnja J Gerrits, Emily A Leven, Andrew L Frelinger, et al.
Journal of the American College of Cardiology|July 26, 2014
Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trialWillibald Hochholzer, Christian T Ruff, Robert A Mesa, et al.
Blood|July 18, 2022
Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 studyMatthew M Heeney, Miguel R Abboud, Jessie Githanga, et al.
Lancet (London, England)|September 4, 2009
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trialsMichelle L O'Donoghue, Eugene Braunwald, Elliott M Antman, et al.
Scientific Reports|May 15, 2024
Dysregulation of platelet serotonin, 14-3-3, and GPIX in sudden infant death syndromeAndrew L Frelinger, Robin L Haynes, Richard D Goldstein, et al.
Circulation|December 7, 2007
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trialStephen D Wiviott, Dietmar Trenk, Andrew L Frelinger, et al.
Diabetologia|December 21, 2019
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertensionJohn P Hanrahan, Jelena P Seferovic, James D Wakefield, et al.
JAMA|November 18, 2011
Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular diseaseJessica L Mega, Willibald Hochholzer, Andrew L Frelinger, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 5, 2017
High serum serotonin in sudden infant death syndromeRobin L Haynes, Andrew L Frelinger, Emma K Giles, et al.
Blood|May 7, 2025
ANKRD26-related Thrombocytopenia 2 with a Baseline Increase in Blasts: Implications for Clinical SurveillanceLara Wahlster, Lucy A Godley, Jason X Cheng, et al.
Pageof 13

Showing results (111-120 of 124) with videos related to

Sort By:
Pageof 13
Blood|July 31, 2015
Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopeniaAnja J Gerrits, Emily A Leven, Andrew L Frelinger, et al.
Journal of the American College of Cardiology|July 26, 2014
Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trialWillibald Hochholzer, Christian T Ruff, Robert A Mesa, et al.
Blood|July 18, 2022
Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 studyMatthew M Heeney, Miguel R Abboud, Jessie Githanga, et al.
Lancet (London, England)|September 4, 2009
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trialsMichelle L O'Donoghue, Eugene Braunwald, Elliott M Antman, et al.
Scientific Reports|May 15, 2024
Dysregulation of platelet serotonin, 14-3-3, and GPIX in sudden infant death syndromeAndrew L Frelinger, Robin L Haynes, Richard D Goldstein, et al.
Circulation|December 7, 2007
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trialStephen D Wiviott, Dietmar Trenk, Andrew L Frelinger, et al.
Diabetologia|December 21, 2019
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertensionJohn P Hanrahan, Jelena P Seferovic, James D Wakefield, et al.
JAMA|November 18, 2011
Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular diseaseJessica L Mega, Willibald Hochholzer, Andrew L Frelinger, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 5, 2017
High serum serotonin in sudden infant death syndromeRobin L Haynes, Andrew L Frelinger, Emma K Giles, et al.
Blood|May 7, 2025
ANKRD26-related Thrombocytopenia 2 with a Baseline Increase in Blasts: Implications for Clinical SurveillanceLara Wahlster, Lucy A Godley, Jason X Cheng, et al.
Pageof 13